AIIMS Director Dr Randeep Guleria hopes for early approval of COVID vaccine Covaxin by WHO
3 years, 2 months ago

AIIMS Director Dr Randeep Guleria hopes for early approval of COVID vaccine Covaxin by WHO

India TV News  

With the data and studies regarding COVID-19 vaccine Covaxin submitted to the World Health Organization, the All India Institute of Medical Sciences Delhi Director Randeep Guleria is hopeful that the authorisation for emergency use listing to the vaccine will be accorded soon. Though individual European countries have recognised the Serum Institute of India's Covishield, however till date the European Union that introduced EU Digital Covid Certificate is yet to give nods for the visa procedures for India. All Data was submitted for Emergency Use Listing Application to World Health Organization in early July. We have responded to any clarifications sought by WHO and are awaiting further feedback,"WHO has so far approved Covid vaccines developed by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China's Sinopharm and Oxford-AstraZeneca for emergency use.

India Covid Bharat Vaccine Covid Vaccine Bharat Biotech Covaxin Emergency Use Guleria Director Hopes  director  hopes  world  covid  data  covaxin  health  india  randeep  vaccine  biotech  guleria  dr  approval  early  emergency

History of this topic

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda
4 months, 3 weeks ago

ICMR got ₹172 cr. from Bharat Biotech for Covaxin: Nadda

The Hindu  

The Indian Council of Medical Research has received ₹172 crore as royalty from Bharat Biotech International Limited for jointly developing Covaxin, an indigenously developed vaccine for COVID-19, Union Health Minister J.P. Nadda said, during Question Hour in the Lok Sabha on Friday. Covaxin was jointly developed by ICMR, National Institute of Virology, and Bharat Biotech International Ltd, in two phases. …

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister
4 months, 3 weeks ago

Bharat Biotech corrects Covaxin patent to include ICMR, NIV after govt objections: Health Minister

New Indian Express  

NEW DELHI: Union health minister J P Nadda on Friday said that Bharat Biotech initially did not mention ICMR and NIV as co-inventors in the patent application for Covaxin and the application was corrected after objections were raised by the government. Covaxin, which was widely used as a Covid vaccine, was jointly developed by the Indian Council of Medical Research, …

The right way to counter a poor Covaxin safety study
4 months, 3 weeks ago

The right way to counter a poor Covaxin safety study

The Hindu  

It took all of five days for the Indian Council of Medical Research to strongly criticise the poor design of the long-term safety study of Covaxin by researchers from the Banaras Hindu University, Varanasi. A publication failure that is glaring Three years after the interim data were posted as a preprint, Bharat Biotech and ICMR are yet to publish any …

BHU study: Over 30 per cent of Covaxin recipients report adverse events
7 months, 1 week ago

BHU study: Over 30 per cent of Covaxin recipients report adverse events

India TV News  

A recent study conducted by researchers at Banaras Hindu University revealed that over 30% of individuals who received Bharat Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious adverse events of special interest such as stroke and Guillain-Barre syndrome reported in one per cent of …

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
7 months, 3 weeks ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

With State prod, India can be world leader in vaccines
10 months, 4 weeks ago

With State prod, India can be world leader in vaccines

Hindustan Times  

The World Health Organization activated its incident management support team as part of its emergency response framework on the emergence of a cluster of atypical pneumonia cases emerging from Wuhan, China, on January 1, 2020. India, the dark horse in the vaccine race, did the unexpected and against all odds, approving EUA to two vaccines — “made in India” Covishield …

COVID-19 update: Union Health Minister Mansukh Mandaviya urges heightened preparedness amidst surge in cases
1 year ago

COVID-19 update: Union Health Minister Mansukh Mandaviya urges heightened preparedness amidst surge in cases

India TV News  

Union Health Minister Mansukh Mandaviya conducted a virtual review meeting on Wednesday, addressing the increasing COVID-19 cases in the country and emphasizing the preparedness of health facilities. As the country faces a surge in COVID-19 cases, the Union Health Minister's call for increased preparedness aligns with the ongoing efforts to manage and mitigate the impact of the virus. The emphasis …

A new regime: On the Emergency Use Authorisation regime in India and clinical trials
1 year, 5 months ago

A new regime: On the Emergency Use Authorisation regime in India and clinical trials

The Hindu  

Last week, the Drug Controller General of India cleared, under the provisions of ‘emergency use authorisation’, a new mRNA vaccine for COVID-19 developed by Pune-based Gennova Biopharmaceuticals, a pioneer in India in developing mRNA vaccines. More than evidence-based assessment, it was a technicality in India’s ‘New Drugs and Clinical Trials Rules, 2019’ that allowed EUA in India for COVID-19 vaccines. …

Serum Institute could resume Covishield production as Covid cases rise
1 year, 8 months ago

Serum Institute could resume Covishield production as Covid cases rise

Live Mint  

The Serum Institute of India could resume production of the Covishield Covid-19 vaccine as infections rise in the country, a company spokesperson said on Wednesday. Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’. Many would perhaps not know that Covishield carries a DNA …

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine
1 year, 10 months ago

Health minister Mandaviya launches Bharat Biotech's nasal Covid vaccine

Hindustan Times  

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday. The nasal vaccine -- BBV154 -- had received the Drugs Controller General of India's approval in November for restricted emergency use among adults as a heterologous booster dose. According to a statement issued …

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC
1 year, 10 months ago

COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

India TV News  

COVID-19 nasal vaccine launch : Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh collectively launched 'iNCOVACC', the world's first made-in-India nasal vaccine on Thursday in the national capital. Who all were present: On the occasion of the launch, the Union Minister of State Science & Technology; Minister of State Earth Sciences; MoS PMO, Personnel, Public …

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose
1 year, 11 months ago

DCGI Approves Market Authorisation for SII's Covid Vaccine Covovax as Heterologous Booster Dose

News 18  

The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India, had recently written to the DCGI for the approval …

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch
1 year, 11 months ago

Covid: 250 million Corbevax, Covaxin in stock, ready for dispatch

Hindustan Times  

Around 250 million Covid vaccines manufactured by two major Hyderabad-based units – Biological E and Bharat Biotech – are ready for dispatch in the market as soon as orders are received. Nearly 200 million Corbevax vaccine of Biological E and 50 million of Bharat Biotech's Covaxin are stockpiled at the moment. Read| Covid drills at hospitals; case count remains low …

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
1 year, 11 months ago

Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses

Live Mint  

The two major Hyderabad-based vaccine manufacturing units, Biological E and Bharat Biotech, together are holding about 250 million Covid vaccine doses ready to dispatch as and when orders are received, according to news agency PTI. Currently, Biological E is holding 200 million doses of its Covid-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses …

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
1 year, 11 months ago

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

India TV News  

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received. Corbevax and Covaxin stocks Biological E held 200 million doses of its …

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster
1 year, 11 months ago

Rs 800 at Pvt Hosps, Rs 325 at Govt Centres: India's 1st Needle-free Nasal Vax, Now Available as Booster

News 18  

A single dose of Bharat Biotech’s intranasal vaccine iNCOVACC is now available on CoWin application for Rs 800, while Rs 325 has been fixed for purchase in government facilities. Provided that private hospitals are permitted to charge up to Rs 150 as an administrative charge for every dose of the Covid-19 vaccine, one dose of this vaccine developed on a …

Indian Army issues advisory on Covid, asks defence personnel to take safety measures
2 years ago

Indian Army issues advisory on Covid, asks defence personnel to take safety measures

India TV News  

The Indian Army issued an advisory on Friday asking defence personnel to take up adequate measures to tackle COVID. The advisory asked them to take up measures such as the usage of face masks in closed or crowded places, practising hand sanitisation, and maintaining social distancing among others. Union Health Minister Dr Mansukh Mandaviya is set to hold a virtual …

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose
2 years ago

SII Seeks Drug Regulator's Nod for Market Authorisation of Covovax Vaccine as Covid-19 Booster Dose

News 18  

The Serum Institute of India has sought the drug regulator’s approval for market authorisation of its COVID-19 vaccine Covovax as a booster dose for those aged 18 years and above who have been administered two doses of Covishield or Covaxin, official sources said on Thursday. Prakash Kumar Singh, director, government and regulatory affairs, SII, submitted a market authorisation application for …

Covid not over yet; need to be alert, increase booster doses uptake: Mandaviya tells Parliament
2 years ago

Covid not over yet; need to be alert, increase booster doses uptake: Mandaviya tells Parliament

Live Mint  

New Delhi: With covid-19 cases surging in China, health minister Mansukh Mandaviya on Thursday urged all members of Parliament to help spread community awareness about the pandemic and the need to remain alert. Presently 153 new cases on an average are being reported daily across the country, but globally approximately 5.87 lakh new cases are still being reported on an …

Covid News Updates: Maha Govt to Set Up Task Force to Keep An Eye on Coronavirus Situation, Coordinate With Centre
2 years ago

Covid News Updates: Maha Govt to Set Up Task Force to Keep An Eye on Coronavirus Situation, Coordinate With Centre

News 18  

Covid-19 News Updates: Amid a surge in Covid-19 cases globally, Union Health Minister Mansukh Mandaviya on Wednesday held over an hour-long review meeting to discuss the coronavirus situation in the country. Advising Indians not to worry amid rising cases in China, Adar Poonawalla, chief executive of Serum Institute of India, said that we need not panic “given our excellent vaccination …

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla
2 years ago

India need not panic given excellent COVID-19 vaccination coverage: Adar Poonawalla

The Hindu  

Serum Institute of India CEO Adar Poonawalla on Tuesday expressed concern over reports of a rising COVID-19 graph in China but said there is no need to panic as the vaccination coverage in India is excellent. Mr. Poonawalla's tweet came a day after the Union Health Ministry urged all states and UTs to ramp up the whole genome sequencing of …

'Rising Covid cases in China concerning,' says Serum Institute's Adar Poonawalla
2 years ago

'Rising Covid cases in China concerning,' says Serum Institute's Adar Poonawalla

Hindustan Times  

Raising concern on the rising COVID-19 cases in neighbouring China, Serum Institute of India CEO Adar Poonawala on Wednesday asked the people not to panic because of India's "excellent vaccination coverage and track record". Expressing concern over the spurt in Covid-19 cases in China, former Indian diplomat KP Fabian on Tuesday said, "over 60 per cent of China and 10 …

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal
2 years ago

Bharat Biotech urges Centre to include its intranasal COVID vaccine in CoWIN portal

Deccan Chronicle  

Hyderabad: Bharat Biotech has requested the central government to include its intranasal COVID-19 vaccine iNCOVACC, in CoWIN portal to enable the recipients of the jab to get vaccination certificate. The company sources said Bharat Biotech is currently holding discussions with international “potential partners” who have approached the company for manufacturing and distribution of the intranasal vaccine globally. “Since iNCOVACC has …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

50 million doses of Covaxin set to expire early 2023 due to poor offtake
2 years, 1 month ago

50 million doses of Covaxin set to expire early 2023 due to poor offtake

The Hindu  

Nearly 50 million doses of Bharat Biotech’s COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said. Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year, though the vaccine maker …

Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval
2 years, 3 months ago

Covid-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval

India TV News  

The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India for the Intranasal Covid-19 vaccine. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19. Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 recombinant nasal vaccine approved by CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for …

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here
2 years, 5 months ago

Corbevax, Covaxin vacines get nod for use among 5-12 years olds; details here

Live Mint  

Biological E's Corbevax and Bharat Biotech's Covaxin on July 8 received the nod from the National Technical Advisory Group on Immunisation's Standing Technical Sub-Committee for use among children aged between 5-12 years. The Drugs Controller General of India granted emergency use authorisation to the Biological E's Corbevax for 5-12 year old and Bharat Biotech's Covaxin for minors belonging to the …

Focus on adequate testing, surveillance: Mandaviya at Covid review meeting
2 years, 6 months ago

Focus on adequate testing, surveillance: Mandaviya at Covid review meeting

India TV News  

Highlights India again reported a rise on Wednesday with 12,249 fresh Covid infections Active caseload of the country has risen to 81,687 India's daily positivity rate was reported at 3.94 per cent Covid-19 cases in India: Union Health Minister Mansukh Mandviya directed the officials to continue to focus on surveillance and whole-genome sequencing to scan for any possible virus mutation …

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed
2 years, 6 months ago

Bharat Biotech Nasal Covid Vaccine's Phase 3 Trials Completed

News 18  

Bharat Biotech on Saturday said that the clinical Phase III trials of the nasal vaccine for Covid-19 have been completed and that the company will submit its data with Drugs Controller General of India next month. Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday said, if everything is okay, then they will get permission to launch …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

Germany recognises Bharat Biotech's Covaxin for travel from June 1
2 years, 6 months ago

Germany recognises Bharat Biotech's Covaxin for travel from June 1

India TV News  

Highlights WHO in November last year issued an emergency use listing for Covaxin The step added a growing portfolio of vaccines validated for the prevention of COVID-19 WHO's EUL procedure assesses the quality, safety and efficacy of COVID-19 vaccines Germany has recognised the WHO-listed Bharat Biotech's COVID vaccine Covaxin, for travel to the country starting June 1. World Health Organization …

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court
2 years, 7 months ago

No Haste In Granting Emergency Use Authorization To Covaxin & Covishield: Supreme Court

Live Law  

In its judgment holding that the policy of the Union Government on COVID-19 vaccination policy is reasonable, the Supreme Court rejected the contention that restricted emergency use approvals had been granted to COVISHIELD and COVAXIN in haste, without thorough review of the relevant data.The court observed that the challenge to the procedures adopted by the expertbodies while granting. "However, it …

SEC seeks more data from Serum Institute of India over COVID vaccine 'Covovax' for 7-12 age group: Sources
2 years, 7 months ago

SEC seeks more data from Serum Institute of India over COVID vaccine 'Covovax' for 7-12 age group: Sources

India TV News  

Highlights DCGI subject expert committee on April 29 sought more data from SII on Covovax vaccine SEC has sought more data for Covovax vaccine for 7-12 years age group Covovax has already been recommended by DCGI for children above 12 years of age Coronavirus vaccine: The Drugs Controller General of India's subject expert committee on Friday sought more data from …

COVID-19: Govt to expedite process of recognition of Biological E Corbevax by other countries
2 years, 7 months ago

COVID-19: Govt to expedite process of recognition of Biological E Corbevax by other countries

The Hindu  

The government plans to expedite the process of recognition of COVID-19 vaccine Corbevax by other countries while its manufacturer Biological E pursues WHO's emergency use listing for the jab being administered in India among the 12-14 years age group. According to an internal document circulated to the members of the Empowered Group-5 on COVID-19 Vaccination, which will be meeting soon, …

In haste: The Hindu Editorial on vaccinating children against COVID-19
2 years, 7 months ago

In haste: The Hindu Editorial on vaccinating children against COVID-19

The Hindu  

The emergency use authorisation granted on April 26 to two COVID-19 vaccines — Corbevax for children 5-11 years, and Covaxin for children 6-11 years — is one more instance where the Indian drug regulator has acted in haste. Even if the EUA granted to Covaxin in January 2021 despite no safety and efficacy data of the phase-3 trial is condoned …

COVID: Over 2,900 new pandemic cases, 32 fatalities in last 24 hours; active cases rise to 16,279
2 years, 7 months ago

COVID: Over 2,900 new pandemic cases, 32 fatalities in last 24 hours; active cases rise to 16,279

India TV News  

Highlights Total active cases of COVID in India have rose to 16,279 today The total death toll in the country is now at 5,23,654 The daily positivity rate is 0.58 per cent on April 27 COVID-19 India News Updates : India recorded 2,927 new cases of the novel coronavirus, along with 32 deaths due to the infection in the past …

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds
2 years, 8 months ago

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds

Deccan Chronicle  

New Delhi: The Subject Expert Committee of the Drug Controller General of India has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said. This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years. However, the …

Govt panel approves use of Corbevax for 5-12 year age group
2 years, 8 months ago

Govt panel approves use of Corbevax for 5-12 year age group

India Today  

Expert panel of Drug Controller General of India -- India’s drug regulator-- has recommended granting emergency use authorisation for Biological E's Covid-19 vaccine Corbevax for children in 5 to 12 years age group. "The Subject Expert Committee on COVID-19 of the CDSCO which deliberated on Biological E's EUA application has recommended granting emergency use authorisation for use of Corbevax in …

COVID-19: Mansukh Mandaviya chairs meeting with key experts on 'XE' variant, directs officials to boost surveillance
2 years, 8 months ago

COVID-19: Mansukh Mandaviya chairs meeting with key experts on 'XE' variant, directs officials to boost surveillance

Firstpost  

Mansukh Mandaviya instructed officials on the medical infrastructure and resources front to constantly review the availability of essential drugs and medicines required for COVID-19 treatment New Delhi: Union Health Minister Mansukh Mandaviya on Tuesday chaired a review meeting regarding the COVID-19 strain – ‘XE variant’ – and directed the officials to boost the ongoing monitoring and surveillance in the country. …

WHO suspends UN supply of Covaxin over manufacturing deficiencies, Bharat Biotech slows down production
2 years, 8 months ago

WHO suspends UN supply of Covaxin over manufacturing deficiencies, Bharat Biotech slows down production

India Today  

In a setback to India’s indigenous vaccine against Covid-19, the World Health Organisation has issued a statement saying that the body is suspending the supply of Bharat Biotech’s Covaxin through UN agencies. A day earlier, Bharat Biotech issued a statement saying the company “announces the temporary slowing down of production of Covaxin across its manufacturing facilities, having completed its supply …

Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies
2 years, 8 months ago

Bharat Biotech says upgrading Covaxin facilities as WHO suspends vaccine supplies

India TV News  

Highlights The WHO has suspended the supply of Covaxin vaccine under the United Nations procurement The development comes after an inspection of the COVID-19 vaccine last month Earlier too, Bharat Biotech had said it is working on further improvements and upgrades Bharat Biotech has said it is working on upgrades to ensure that the production of Covaxin continues to meet …

WHO pauses Covaxin supply via UN bodies
2 years, 8 months ago

WHO pauses Covaxin supply via UN bodies

The Hindu  

Bharat Biotech to upgrade facility The World Health Organisation on Saturday suspended supply of Bharat Biotech’s COVID vaccine, Covaxin, to allow the manufacturer to upgrade facilities and address deficiencies found during an inspection last month. ‘Will meet standards’ In a statement issued on April 1, Bharat Biotech said it was fully committed to implementing facility improvements and upgrades to ensure …

WHO suspends Covaxin supply to UN agencies
2 years, 8 months ago

WHO suspends Covaxin supply to UN agencies

Deccan Chronicle  

Hyderabad: The World Health Organization has confirmed it has suspended the supply of Covaxin, produced by city-based Bharat Biotech, through UN procurement agencies and recommending to countries that received the covid vaccine to take actions as appropriate. A statement issued by WHO on Saturday said the suspension is in response to the outcomes of its post EUL inspection held between …

WHO suspends international supply of Covaxin via UN procurement
2 years, 8 months ago

WHO suspends international supply of Covaxin via UN procurement

India Today  

The World Health Organization in a statement issued on April 2 confirmed the suspension of supply of Covaxin produced by Bharat Biotech, through UN procurement agencies and gave recommendation to the countries that received the vaccine to take actions as appropriate. On April 1, the Indian vaccine manufacturer Bharat Biotech issued a statement announcing the “temporary slowing down of Covaxin …

Bharat Biotech says slowing down Covaxin production for facility optimisation
2 years, 8 months ago

Bharat Biotech says slowing down Covaxin production for facility optimisation

India TV News  

Highlights Bharat Biotech said it is temporarily slowing down production of its COVID-19 vaccine Covaxin. Company said 'will focus on pending facility maintenance, process, facility optimisation activities' Bharat Biotech on Friday said it is temporarily slowing down production of its COVID-19 vaccine Covaxin across its manufacturing units for facility optimisation as it has already completed its supply obligations to procurement …

India's drugs regulator approves phase-3 trial of covid vaccine covovax
2 years, 9 months ago

India's drugs regulator approves phase-3 trial of covid vaccine covovax

India Today  

The Drugs Controller General of India granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults, official sources said. The Subject Expert Committee on Covid-19 of the Central Drugs Standard Control Organisation had, on March 5, recommended permission for conducting the phase-3 clinical trial for Covovax as a booster dose …

Bharat Biotech, SII Oppose Plea In Supreme Court For Public Disclosure Of Vaccine Trial Data
2 years, 9 months ago

Bharat Biotech, SII Oppose Plea In Supreme Court For Public Disclosure Of Vaccine Trial Data

Live Law  

Vaccine manufactures Bharat Biotech Ltd and Serum Institute of India opposed a petition in the Supreme Court seeking disclosure of the data on clinical trial and adverse events following immunization in relation to Covaxin and Covishield vaccines developed by them respectively against COVID-19 pandemic.A bench comprising Justices L Nageswara Rao and BR Gavai was hearing a writ petition filed. Vaccine …

Health Minister Mandaviya directs officials to be alert as Covid cases spike in China, other countries
2 years, 9 months ago

Health Minister Mandaviya directs officials to be alert as Covid cases spike in China, other countries

India Today  

A High-Level meeting was chaired by the Union Health Minister Mansukh Mandaviya on Wednesday on the rising number of Covid cases in China and other countries, according to the sources. According to officials in the health ministry, the Union Health Minister has directed officials for strict compliance in three aspects: High level of alertness on the case rise, intensified surveillance …

COVID: India's vaccination coverage crosses 180 crore landmark
2 years, 9 months ago

COVID: India's vaccination coverage crosses 180 crore landmark

India TV News  

Highlights India's COVID-19 vaccination coverage crossed 180 crore landmark milestone on March 12 Over 2.12 cr Precaution Doses for identified categories of beneficiaries have also been administered Dr Mansukh Mandaviya congratulated the nation on achieving this historic landmark With the administration of more than 17 lakh vaccine doses, India's COVID-19 vaccination coverage crossed 180 crore landmark milestone on Saturday, informed …

DCGI Grants Emergency Use Authorisation to SII's Covid Vaccine Covovax for 12-17 Age Group
2 years, 9 months ago

DCGI Grants Emergency Use Authorisation to SII's Covid Vaccine Covovax for 12-17 Age Group

News 18  

India’s central drug regulator on Wednesday granted emergency use authorisation to Serum Institute of India’s Covid-19 vaccine Covovax for the 12-17 age group subject to certain conditions. Confirming the DCGI approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted:"@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults …

Discover Related